3.1 Patients
Of the 70 patients that were recruited for trial eligibility, 43
patients (n=21 in the CSO group and n=22 in the placebo group) completed
the study. Fig. 1 shows the study flow chart and a description of the
causes for the loss to follow up. Overall, 90.5% of participants were
compliant with supplements, by the end of the trial. Any adverse effects
were reported by patients with SFO and CSO consumption. There was no
difference between groups in any of the demographic variables including
gender, age, employment, education level, marital status and PAL.